DOCUMENT RESOURCES FOR EVERYONE
Documents tagged
Education of patients taking capecitabine EORTC 10041 BIG 3-04 Intergroup Study MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy): A.
Documents Education of patients taking capecitabine EORTC 10041 BIG 3-04 Intergroup Study MINDACT (Microarray....

Slide 1Education of patients taking capecitabine EORTC 10041 BIG 3-04 Intergroup Study MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy): A prospective,…

Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV.
Documents Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with...

Slide 1www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV co-infected…

Loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi: Understanding outcomes and reasons Hannock Tweya, Salem Gugsa, Mina Hosseinipour,
Documents Loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi: Understanding...

Slide 1Loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi: Understanding outcomes and reasons Hannock Tweya, Salem Gugsa, Mina Hosseinipour, Colin…

Gary Hampton - Aids Dementia & HIV Psychiatry Service - SESSION 1: Breaking Out: HIV Treatment and Care when PLWHIV (People Living with HIV) Transition from Custodial Settings into
Health & Medicine Gary Hampton - Aids Dementia & HIV Psychiatry Service - SESSION 1: Breaking Out: HIV Treatment and.....

1. PRESENTERTITLEPH, EMAIL...BREAKING OUT: HIV TREATMENT AND CARE WHEN PLWHIV TRANSITION FROM CUSTODIAL SETTINGS INTO THE COMMUNITY Gary Hampton, Michelle Merry, Leo Barreto,…

Profesional natalizumab benefit risk update may 2013
Business Profesional natalizumab benefit risk update may 2013

1. TY-PAN-0597 Date of preparation: May 2013FOR HEALTHCARE PROFESSIONALS ONLYTYSABRI (natalizumab)Benefit/Risk Update &PML Risk Stratification 2. TY-PAN-0597 Date of…

Natalizumb benefit risk update August 2013
Business Natalizumb benefit risk update August 2013

1. TY-PAN-0597(3) Date of preparation: August 2013FOR HEALTHCARE PROFESSIONALS ONLY TYSABRI (natalizumab) Benefit/Risk Update & PML Risk Stratification 2. TY-PAN-0597(3)…

Natalizumab safety and pml risk stratification march 2013
Health & Medicine Natalizumab safety and pml risk stratification march 2013

1. Natalizumab Safety Update & PML Risk Stratification Professor Gavin GiovannoniBarts and The LondonTY-PAN-0587(2) Date of preparation: March 2013 2. Benefit / Risk…

Tysabri benefit risk update july 2013 (ty-pan-0597(2))
Business Tysabri benefit risk update july 2013 (ty-pan-0597(2))

1. TY-PAN-0597(2) Date of preparation: July 2013FOR HEALTHCARE PROFESSIONALS ONLY TYSABRI (natalizumab) Benefit/Risk Update & PML Risk Stratification 2. TY-PAN-0597(2)…

Natalizumab benefit risk update january 2014
Health & Medicine Natalizumab benefit risk update january 2014

1. Tysabri (natalizumab) Benefit/Risk Update & PML Risk StratificationFOR HEALTHCARE PROFESSIONALS ONLYTY-PAN-0597(8) Date of preparation: January 2014 2. Benefit…

Natalizumab Safety Update September 2012
Health & Medicine Natalizumab Safety Update September 2012

1. Natalizumab Safety Update & PMLRisk StratificationBarts Health September 2012 Gavin GiovannoniProfessor of NeurologyTY-PAN-0463r Date of preparation: September…

Popular Categories
Relevant Tags